Click a keyword to view all the abstracts on this site tagged with that keyword.
- Diagnostic Tests and connective tissue diseases
- Diagnostic Tests and fibromyalgia
- Diagnostic Tests and nervous system lupus
- Diagnostic Tests and rheumatoid arthritis (RA)
- Diagnostic Tests and Sjogren's syndrome
- diet
- diet and rheumatoid arthritis (RA)
- diet and risk
- dietary protein intake
- dietary supplements
- dietary supplements and epidemiologic methods
- Dietary supplements and osteoporosis
- Dietary supplements and rheumatoid arthritis
- differential diagnosis
- differential diagnosis and familial Mediterranean fever
- Differential diagnosis and gout
- differential diagnosis and immune response
- differential diagnosis and psoriatic arthritis
- differential diagnosis and rheumatoid arthritis (RA)
- differential diagnosis and spondylarthritis
- differentiation
- differentiation and chronic inflammation
- differentiation and Treg
- Diffuse idiopathic skeletal hyperostosis (DISH)
- diffuse idiopathic skeletal hyperostosis (DISH) and genetics
- Diffuse idiopathic skeletal hyperostosis (DISH) and gout
- diffuse idiopathic skeletal hyperostosis (DISH) and morbidity and mortality
- digital
- digital technologies
- digital technologies and patient outcomes
- digital ulcers
- Digital X-ray Radiogrammetry (DXR)
- Digital X-ray Radiogrammetry (DXR) and Early Rheumatoid Arthritis
- Dipping and inflammatory markers
- DIRA and anti-TNF therapy
- direct and Biologics
- direct effect and indirect effect
- Disability
- Disability and education
- Disability and fibromyalgia
- Disability and gout
- disability and grip strength
- disability and HAQ
- disability and longitudinal studies
- Disability and menopause
- disability and morbidity and mortality
- Disability and musculoskeletal disorders
- disability and osteoarthritis
- disability and primary care
- disability and quality of life
- disability and rheumatoid arthritis
- Disability and rheumatoid arthritis (RA)
- disability and scleroderma
- disability and vasculitis
- disability and work
- Disaster planning
- discoid lupus and innate immunity
- discoid lupus erythematosus
- discontinuation
- Discordance
- discrete choice experiment
- diseae activity
- Disease Activity
- Disease Activity and activity score
- disease activity and adoption
- Disease Activity and adult-onset Still's disease
- Disease Activity and ankylosing spondylitis (AS)
- Disease Activity and atherosclerosis
- Disease Activity and axial spondyloarthritis
- Disease Activity and Biologics
- Disease Activity and biomarkers
- Disease Activity and body mass index
- Disease Activity and chemokines
- Disease Activity and chronic disease care
- Disease Activity and clinical trials
- Disease Activity and comorbidity
- Disease Activity and corticosteroids
- Disease Activity and cutaneous lupus
- Disease Activity and diagnostic imaging
- Disease Activity and DMARDs
- Disease Activity and flare
- Disease Activity and functional status
- Disease Activity and gout
- Disease Activity and histopathologic
- Disease Activity and inflammation
- Disease Activity and interferons
- Disease Activity and interleukins (IL)
- Disease Activity and joints
- Disease Activity and juvenile dermatomyositis
- Disease Activity and juvenile idiopathic arthritis (JIA)
- Disease Activity and large vessel vasculitis
- Disease Activity and longitudinal studies
- Disease Activity and lupus nephritis
- Disease Activity and methotrexate (MTX)
- Disease Activity and obesity
- Disease Activity and outcome measures
- Disease Activity and outcomes
- Disease Activity and pain
- Disease Activity and patient engagement
- Disease Activity and patient outcomes
- Disease Activity and patient-reported outcome measures
- Disease Activity and psoriatic arthritis
- Disease Activity and quality of life
- Disease Activity and race/ethnicity
- Disease Activity and radiography
- Disease Activity and remission
- Disease Activity and rheumatic disease
- Disease Activity and rheumatoid arthritis
- Disease Activity and rheumatoid arthritis (RA)
- Disease Activity and rheumatologic disease
- Disease Activity and self-management
- Disease Activity and Sjogren's syndrome
- Disease Activity and SLE
- Disease Activity and spondylarthritis
- Disease Activity and systemic lupus erythematosus (SLE)
- Disease Activity and T-Regulatory Cells
- Disease Activity and Takayasu.s arteritis
- Disease Activity and ultrasonography
- disease burden and climate
- Disease domain
- Disease duration
- disease management
- Disease Sub-phenotyping
- Disease Sub-phenotyping and prognostic factors
- Disease susceptibility
- disease susceptibility and informatics
- disease susceptibility and rheumatoid arthritis (RA)
- disease susceptibility and toll-like receptors
- Disease-modifying antirheumatic drugs
- Disease-Modifying Antirheumatic Drugs (Dmards)
- disease-modifying antirheumatic drugs and anti-CCP antibodies
- disease-modifying antirheumatic drugs and Biologics
- disease-modifying antirheumatic drugs and intima medial thickness
- disease-modifying antirheumatic drugs and methotrexate (MTX)
- disease-modifying antirheumatic drugs and orthopedics
- disease-modifying antirheumatic drugs and outcomes
- disease-modifying antirheumatic drugs and psoriatic arthritis
- disease-modifying antirheumatic drugs and registry
- disease-modifying antirheumatic drugs and rheumatoid arthritis
- disease-modifying antirheumatic drugs and rheumatoid arthritis (RA)
- disease-modifying antirheumatic drugs and safety
- Disparities
- distance and pediatric rheumatology
- diversity and Sjogren's syndrome
- DMARD-free remission and Disease Activity
- DMARDs
- DMARDs and access to care
- DMARDs and azathioprine
- DMARDs and cardiovascular disease
- DMARDs and claims
- DMARDs and clinical trials
- DMARDs and combination therapies
- DMARDs and cytokines
- DMARDs and diabetes mellitus
- DMARDs and Disease Activity
- DMARDs and Early Rheumatoid Arthritis
- DMARDs and economics
- DMARDs and health care cost
- DMARDs and hepatitis
- DMARDs and IL-17
- DMARDs and inflammation
- DMARDs and Intervention
- DMARDs and Janus kinase (JAK)
- DMARDs and methotrexate (MTX)
- DMARDs and obesity
- DMARDs and outcome measures
- DMARDs and outcomes
- DMARDs and patient assistance
- DMARDs and patient outcomes
- DMARDs and patient questionnaires
- DMARDs and patient-reported outcome measures
- DMARDs and pregnancy
- DMARDs and qualitative
- DMARDs and rheumatoid arthritis
- DMARDs and rheumatoid arthritis (RA)
- DMARDs and seronegative spondyloarthropathy
- DMARDs and systemic lupus erythematosus (SLE)
- DMARDs and tofacitinib
- DMARDs and treatment
- DMARDs and tuberculosis
- DMARDs and tumor necrosis factor (TNF)
- DMOAD
- DMOAD and joint protection
- DMOAD and osteoarthritis
- DNA
- DNA and Genetic Biomarkers
- DNA and NET
- DNA degradation
- DNA Methylation
- DNA Methylation and polyangiitis
- DNA Methylation and rheumatoid arthritis (RA)
- DNA sensing
- DOCK8
- DOCK8 and anti-dsDNA
- doctor-patient relationship
- doctor-patient relationship and A3 Adenosine receptor
- doctor-patient relationship and patient outcomes
- doctor-patient relationship and rheumatoid arthritis (RA)
- documentation
- dopamine agonists